VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with symptomatic FAI                      │ Patients with symptomatic FAI                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical and radiographic evidence of FAI          │ Clinical and radiographic evidence of FAI          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients able to provide consent to study          │ Patients able to provide consent to study          │     100 │
│ participation                                      │ participation                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Completion of 6 weeks of physical therapy program  │ Completion of 6 weeks of physical therapy program  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with clinically significant               │ Patients with clinically significant               │     100 │
│ cardiovascular, renal, hepatic, endocrine disease, │ cardiovascular, renal, hepatic, endocrine disease, │         │
│ cancer or diabetes                                 │ cancer or diabetes                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with ongoing infection including HIV and  │ Patients with ongoing infection including HIV and  │     100 │
│ Hepatitis                                          │ Hepatitis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient with history of osteomyelitis/septic       │ Patient with history of osteomyelitis/septic       │     100 │
│ arthritis                                          │ arthritis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticoagulation therapy                            │ Anticoagulation therapy                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are pregnant or breast feeding        │ Patients who are pregnant or breast feeding        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with systemic, rheumatic or inflammatory  │ Patients with systemic, rheumatic or inflammatory  │     100 │
│ disease of the knee or chondrocalcinosis,          │ disease of the knee or chondrocalcinosis,          │         │
│ hemochromatosis, inflammatory arthritis,           │ hemochromatosis, inflammatory arthritis,           │         │
│ arthropathy of the knee associated with juxta-     │ arthropathy of the knee associated with juxta-     │         │
│ articular Paget's disease of the femur or tibia,   │ articular Paget's disease of the femur or tibia,   │         │
│ hemophilic arthropathy, infectious arthritis,      │ hemophilic arthropathy, infectious arthritis,      │         │
│ Charcot's knee joint, villonodular synovitis, and  │ Charcot's knee joint, villonodular synovitis, and  │         │
│ synovial chondromatosis                            │ synovial chondromatosis                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients taking immunosuppressant medication       │ Patients taking immunosuppressant medication       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with abnormal hematology or serum         │ Patients with abnormal hematology or serum         │     100 │
│ chemistry lab results                              │ chemistry lab results                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients receiving injection to treatment knee     │ Patients receiving injection to treatment knee     │     100 │
│ within 2 months of study enrollment                │ within 2 months of study enrollment                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI greater than 35 or less than 20                │ BMI greater than 35 or less than 20                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Established Osteoarthritis (Kellgren-Lawrence \>   │ Established Osteoarthritis (Kellgren-Lawrence > 3) │      99 │
│ 3)                                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Minimum joint space \> 2 mm as measured on AP      │ Minimum joint space > 2 mm as measured on AP       │      99 │
│ radiograph                                         │ radiograph                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hip dysplasia (center edge angle \< 20° on AP      │ Hip dysplasia (center edge angle < 20° on AP       │      99 │
│ radiograph)                                        │ radiograph)                                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Minimum joint space > 2 mm as measured on AP │      41 │
│                                   │ radiograph                                   │         │
├───────────────────────────────────┼──────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 45 Years │ Minimum joint space > 2 mm as measured on AP │      41 │
│                                   │ radiograph                                   │         │
╘═══════════════════════════════════╧══════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 93.63157894736842
OverAll Ratio: 95.31578947368422
